𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma

✍ Scribed by Zhichao Zhou; Hui Guan; Xiaoping Duan; Eugenie S. Kleinerman

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
440 KB
Volume
104
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Primary tumor dependent inhibition of tu
Primary tumor dependent inhibition of tumor growth, angiogenesis, and perfusion of secondary breast cancer in bone
✍ Christian Schaefer; Malte Schroeder; Ina Fuhrhop; Lennart Viezens; Jasmin Otten; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 214 KB

## Abstract The systemic balance of angiogenic and anti‐angiogenic factors has been proposed to play a key‐role in primary tumor growth dependent growth suppression of secondary tumors. Despite the importance of the organ microenvironment to angiogenesis and microcirculation, the influence of a pri

Bone scintigraphy in nonsurgically treat
Bone scintigraphy in nonsurgically treated Ewing's sarcoma at diagnosis and follow-up: Prognostic information of the primary tumor site
✍ Hugenholtz, Elise A. L. ;Piers, Do A. ;Kamps, Willem A. ;Cohen, Ian J. ;Lerman, 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 377 KB

## Abstract In order to detect skeletal metastases in patients with Ewing's sarcoma, bone scanning is commonly used. However, little information is available about the scintigraphic aspects of the primary Ewing's sarcoma during non‐surgical treatment and follow‐up. We studied retrospectively the si

Sustained inhibition of tumor growth and
Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model
✍ Penelope D. Ottewell; Diane V. Lefley; Simon S. Cross; C. Alyson Evans; Robert E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 390 KB

## Abstract Combination therapy, using agents that target the microenvironment as well as the cancer cells, is common in the treatment of advanced breast cancer. Here, we show that a 6‐week course of weekly sequential administration of the cytotoxic drug doxorubicin (2 mg/kg), followed 24 hr later